|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,647.00 GBX | +0.81% |
|
+5.36% | +13.21% |
| 07:15am | AstraZeneca Price Target Up as Berenberg Notes Phase 3 Readout Success Potential | MT |
| 05:51am | Gensight Biologics Announces Executive Changes | CI |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 131,259 | 182,034 | 209,442 | 209,268 | 203,171 | 325,673 | 325,673 | - |
| Change | - | 38.68% | 15.06% | -0.08% | -2.91% | 60.29% | 0% | - |
| Enterprise Value (EV) 1 | 143,126 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 344,359 | 336,839 |
| Change | - | 44.22% | 12.57% | -0.25% | -1.74% | 36.64% | -0.92% | -2.18% |
| P/E ratio | 41x | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 26.6x | 23.4x |
| PBR | 8.4x | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 6.15x | 5.41x |
| PEG | - | -15.2x | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.7x |
| Capitalization / Revenue | 4.93x | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 5.21x | 4.9x |
| EV / Revenue | 5.38x | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 5.51x | 5.07x |
| EV / EBITDA | 17.2x | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 15.2x | 13.6x |
| EV / EBIT | 19.5x | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 16.3x | 14.4x |
| EV / FCF | 37.3x | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 31.9x | 25x |
| FCF Yield | 2.68% | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.13% | 3.99% |
| Dividend per Share 2 | 2.8 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.329 | 3.54 |
| Rate of return | 2.8% | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.59% | 1.69% |
| EPS 2 | 2.44 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.887 | 8.99 |
| Distribution rate | 115% | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.2% | 39.4% |
| Net sales 1 | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 62,545 | 66,462 |
| EBITDA 1 | 8,311 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,616 | 24,801 |
| EBIT 1 | 7,340 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,083 | 23,382 |
| Net income 1 | 3,196 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,428 | 14,088 |
| Net Debt 1 | 11,867 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 18,686 | 11,166 |
| Reference price 2 | 99.99 | 117.51 | 135.16 | 135.02 | 131.05 | 209.98 | 209.98 | 209.98 |
| Nbr of stocks (in thousands) | 1,312,660 | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,945 | 1,550,945 | - |
| Announcement Date | 2/11/21 | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.11x | 5.93x | 17.67x | 1.55% | 326B | |
| 31.01x | 11.75x | 23.61x | 0.64% | 926B | |
| 24.77x | 6.01x | 16.36x | 2.18% | 586B | |
| 65.02x | 7.68x | 19.02x | 2.81% | 412B | |
| 19.35x | 4.81x | 11.94x | 2.72% | 382B | |
| 21.99x | 6.1x | 15x | 2.65% | 317B | |
| 15.7x | 5.03x | 10.98x | 2.66% | 302B | |
| 14.77x | 5.12x | 10.74x | 3.51% | 218B | |
| 25.23x | 6.36x | 11.23x | 2.69% | 201B | |
| 22.77x | 7.04x | 12.87x | 2.14% | 193B | |
| Average | 27.37x | 6.58x | 14.94x | 2.35% | 386.18B | |
| Weighted average by Cap. | 29.15x | 7.39x | 16.76x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
